US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs.
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
3don MSN
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback